Nkarta, Inc. announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Dr. Mahmood will remain with Nkarta until June 30, 2023, to ensure a smooth transition. Nkarta remains on track to announce updated results from its ongoing clinical trial of NKX101 in the second quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.95 USD | +6.43% | +1.02% | +5.30% |
05-09 | Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-26 | Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.30% | 460M | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- NKTX Stock
- News Nkarta, Inc.
- Nkarta, Inc. Announces Resignation of Nadir Mahmood as Chief Financial and Business Officer